Cardiorenal syndrome and iron supplementation-more benefits than risks: a narrative review.
Study Goal
The researchers aimed to review the impact of intravenous iron therapy on clinical outcomes in patients with cardiorenal syndrome (CRS) and iron deficiency, with or without anemia.
Results Summary
Intravenous iron supplementation improved anemia, symptoms, functional capacity, and quality of life in patients with heart failure (HF) and iron deficiency, while also reducing HF-related hospitalizations. Emerging evidence suggests potential benefits for kidney function in CRS patients.
Population
Patients with cardiorenal syndrome (CRS) and iron deficiency, with or without anemia.
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
intravenous iron administration | neutral | patients with cardiorenal syndrome (CRS) and iron deficiency | patients with cardiorenal syndrome (CRS) and iron deficiency | - | emerged as a crucial intervention for managing | #1 |
intravenous iron supplementation | increase | anemia, symptoms, and functional capacity | patients with HF and iron deficiency | - | demonstrated the benefits in improving | #2 |
iron supplementation | decrease | hospitalizations for HF exacerbation | - | - | associated with a reduction in | #3 |
iron supplementation | increase | patients' quality of life and clinical outcomes | - | - | associated with the improvement of | #4 |
intravenous iron therapy | increase | kidney function | patients with CRS | - | suggests a potential positive impact on | #5 |
intravenous iron therapy | increase | estimated glomerular filtration rate | patients receiving intravenous iron therapy | - | shown an increase in | #6 |
intravenous iron therapy | increase | renal function markers | patients receiving intravenous iron therapy | - | improvements in | #7 |
Intravenous iron administration has emerged as a crucial intervention for managing patients with cardiorenal syndrome (CRS) and iron deficiency, with or without the presence of anemia. Multiple studies have demonstrated the benefits of intravenous iron supplementation in improving anemia, symptoms, and functional capacity in patients with HF and iron deficiency. Furthermore, iron supplementation has been associated with a reduction in hospitalizations for HF exacerbation and the improvement of patients' quality of life and clinical outcomes. In addition to its effects on HF management, emerging evidence suggests a potential positive impact on kidney function in patients with CRS. Studies have shown an increase in estimated glomerular filtration rate and improvements in renal function markers in patients receiving intravenous iron therapy, highlighting the potential of this intervention in patients with CRS. This paper reviews the existing literature on the impact of intravenous iron therapy in these patient populations and explores its effects on various clinical outcomes. Future research endeavors are eagerly awaited to further improve our understanding of its clinical implications and optimize patient outcomes.